News

Press releases and news from regional sources, click on original post link to read the full article and see what’s trending. Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

September 29, 2026 SDBN Comments Off on TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

SAN DIEGO–(BUSINESS WIRE)–TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer

September 29, 2026 SDBN Comments Off on Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer

SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN. Click here to view original post Click Here to Publish/Feature Your Company or Product […]

No Picture
News

CytoHub Co-Founder Aitor Aguirre Named to Lead Cardiac Tissue Engineering at NIH's First National Organoid Center

September 29, 2026 SDBN Comments Off on CytoHub Co-Founder Aitor Aguirre Named to Lead Cardiac Tissue Engineering at NIH's First National Organoid Center

SAN DIEGO–(BUSINESS WIRE)–CytoHub Inc., a biotechnology company utilizing the CardioVive AI-integrated human heart assembloid platform for drug safety and efficacy prediction, today announced that Scientific Co-Founder Aitor Aguirre, PhD, has been appointed to key leadership […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

September 28, 2026 SDBN Comments Off on Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, […]

News

How Close Are We to Artificial Superintelligence?

September 28, 2026 SDBN Comments Off on How Close Are We to Artificial Superintelligence?

Could artificial superintelligence be closer than we think? UC San Diego philosopher Eddy Keming Chen discusses recent advances in AI, the prospect of machines surpassing human intelligence and how society can thoughtfully navigate increasingly capable […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

HUNGER ACTION HEROES UNITE! RALLIES STUDENTS IN ALL 50 STATES TO TAKE ACTION AGAINST HUNGER AND FOOD WASTE IN FREE NATIONAL CHALLENGE

September 28, 2026 SDBN Comments Off on HUNGER ACTION HEROES UNITE! RALLIES STUDENTS IN ALL 50 STATES TO TAKE ACTION AGAINST HUNGER AND FOOD WASTE IN FREE NATIONAL CHALLENGE

Students in grades 4 through 9, across all 50 states and D.C., are encouraged to take action on hunger or food waste during Food Waste Prevention Week SAN DIEGO, Sept. 28, 2026 /PRNewswire/ — At […]


ADVERTISEMENT — Advertise With Biotech Networks
News

MEDIMPACT DATA BREACH: Edelson Lechtzin LLP Launches Investigation Into Exposure of Social Security Numbers and Health Information

September 26, 2026 SDBN Comments Off on MEDIMPACT DATA BREACH: Edelson Lechtzin LLP Launches Investigation Into Exposure of Social Security Numbers and Health Information

National class action firm Edelson Lechtzin LLP is offering free case evaluations to individuals affected by the MedImpact Healthcare Systems data breach, which may have exposed names, Social Security numbers, and sensitive health information. SAN […]

No Picture
News

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

September 25, 2026 SDBN Comments Off on Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

L?kahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

September 25, 2026 SDBN Comments Off on L?kahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–L?kahi Therapeutics™ partners with Pepperdine E2B™ to expand ai² Pipeline™, engaging MBA students in evaluating biopharmaceutical assets. Click here to view original post Click Here to Publish/Feature Your Company […]

No Picture
News

Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein, a First-in-Class adjunct in the real-time intraoperative visualization of nerves during head and neck surgical procedures in adults

September 25, 2026 SDBN Comments Off on Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein, a First-in-Class adjunct in the real-time intraoperative visualization of nerves during head and neck surgical procedures in adults

SAN DIEGO–(BUSINESS WIRE)–Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery

September 24, 2026 SDBN Comments Off on ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ — Recently, ACROBiosystems unveiled its latest innovation portfolio—ACRO AIx, CHO-Direct and GlobalLifeShip cross border supply chain to respond the demand of AIDD era. As artificial intelligence becomes increasingly integrated […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma

September 24, 2026 SDBN Comments Off on Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Primmune Therapeutics, a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 […]

No Picture
News

BioTools Innovator Announces the 2026 Finalists

September 24, 2026 SDBN Comments Off on BioTools Innovator Announces the 2026 Finalists

LOS ANGELES–(BUSINESS WIRE)– #BTI–BioTools Innovator names 4 finalists (Caravel, eGlint, Pando Bioscience, QuantumCyte) to compete for $250K at Oct 14 Capstone in San Diego. Click here to view original post Click Here to Publish/Feature Your […]

No Picture
News

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

September 24, 2026 SDBN Comments Off on Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions […]


ADVERTISEMENT — Advertise With Biotech Networks
News

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

September 24, 2026 SDBN Comments Off on Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent […]

No Picture
News

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

September 24, 2026 SDBN Comments Off on MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today […]

No Picture
News

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

September 23, 2026 SDBN Comments Off on Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #65Roses–Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from […]